J&J SECURES TOPAMAX INJUNCTION

At the request of Ortho-McNeil, a Johnson & Johnson (J&J) subsidiary, a court has issued a preliminary injunction against Mylan's generic topiramate product.

The U.S. District Court for the District of New Jersey granted the injunction, preventing Mylan from launching a generic version of the epilepsy drug Topamax (topiramate), J&J announced Oct. 20. Mylan will not be able to market a version of this drug before a final court decision on the validity of J&J's patent. A trial date has not yet been set, and the patent is set to expire in September 2008.

Topamax is indicated for use in epilepsy patients and to treat migraines.